Can this drug cross the Brain's barrier to fight tumors?
NCT ID NCT05804227
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial is testing whether the drug ulixertinib can cross the blood-brain barrier in people with recurrent brain tumors called gliomas. About 40 adults will take the drug before surgery to see how much reaches the tumor and how safe it is. The goal is to learn if this approach could work for future treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOMAS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Brain tumor drug vorasidenib tested in everyday practice
- AI reads MRI scans to predict brain tumor type before surgery
- Brain tumor chemo delivered by pump shows promise in tiny safety trial
- New PET scan could slash radiation by 100x
- SmartMatch: could a lab test find the right drug for your brain tumor?
- 450 brain tumor patients reveal key survival clues